I reckon I'll buy some landscaping machinery and a truck before I ever sign up for that distopian nightmare. At least sound ordinance would prevent 24/7 operation.
A lot of people with ADHD that have success with medication can tell you that it's not just about work.
It also helps with non-work stuff that's just not fun to do, such as chores or filing your taxes. It even helps you stick with hobbies you actually enjoy but your brain gets bored of.
on the recreational level, maybe, but from a therapeutic perspective for people who actually benefit from its prescribed use its absolutely game-changing to live a life without (or with mitigated) executive dysfunction.
I know you're joking but I saw a company that had similar policies like fasting and stuff like that to improve productivity. They seemed to take it pretty seriously...
My partner has had idiopathic hypersomnia (sleeps 12 hours most days, as much as 18 hours some days) for a few years now, and so far nothing we’ve tried has worked without awful side effects (e.g. constant heart palpitations and panic attacks.)
I had been looking into orexin agonists (along with other things like H3 autoreceptor antagonists) back when they were just a concept. It’s good to see them finally reaching commercialization. Although they’re not approved by our own (Canadian) regulatory body quite yet.
Now that they’re approved in the US, though, I’m looking very much forward to seeing how these drugs perform in off-label-ish treatment of the various other sleep disorders that I’m sure clinicians will now begin throwing them at.
Have they tried GHB? I know it's used in narcolepsy patients with great success. If you "microdose" it, it's also one of the best drugs on the planet. Slippery slope, though.
It sounds like is a genuine treatment for those who suffer from narcolepsy, and everything else is merely speculative and has seem pretty bad side-effects.
There is evidence that some forms of ADHD are effectively just the brain falling asleep rapidly and then waking up. This form cam be attenuated with norepinephrine reuptake inhibitor alone. Presents with ADHD like symptoms. But it’s a new thing most likely. Called “Cognitive Disengagement Syndrome”.
> IMO the much more likely explanation is that the brain uses contrastive learning somewhere. [...] Instead of using calculus and outer products to calculate derivatives, you feed real data and false data forward through the network and each neuron tracks and trains on the difference.
That's a technique that was tried in machine learning and worked (although obviously not optimally or we'd all be using it by now) and then we hypothesised that animal brains use it because it would explain sleep.
Despite the stigma surrounding semaglutide, its impact across various health conditions has been remarkable. Bringing that same level of innovation to cognitive disorders could be truly transformative for society
If this means I don't have to take Methylphenidate to function 100% all the time and as a result feel tremendously anxious 100% all the time. SIGN ME UP.
Adding guanfacine (Intuniv) to my methylphenidate took the weird anxious-angry edge off. Would be nice to not have to take one med to fix the side effects of the other, though.
Everyone involved in a stock market agrees it's quite useful to have a separation between days, although you could have a 23.5/7 stock market with only half hour day-ends. That's when things like index rebalancing, addition, removal, stock splits occur. You say whoever holds stock X at end of a certain day holds stock Y+Z at the start of the next day (due to a company splitting up) and there's no need to argue about which millisecond a trade occurred. (It's your own damn fault if you were trying to buy the stock in the milliseconds before closing, but some exchanges run a special closing auction with a different algorithm to prevent races). It's also the time you can deploy software, which you can't do during the day. Maybe half an hour is too short for all this stuff. Or maybe it should be a 12 hour window once a week instead.
I’m not about to stifle research into genuinely useful therapies just because some aspects of society will abuse the absolute shit out of them, and these therapies seem profoundly useful to those who suffer from the mentioned ailments.
Here’s the thing: what a lot of these drugs are doing are basically acting as equivalents to the store-bought neurotransmitters you’d find in things like SSRIs or -phetamines/stimulants. To people lacking in these substances, they’re game changers.
The problem right now is a mismatch between regulation, availability, and testing regimes. Regulations are meant to prevent dystopian shit like employers mandating (or encouraging) a drug regimen for employment through threat of punitive fines or prosecution, while the private insurance markets promote unaffordability domestically (as North America is where over half of pharma revenues come from) and testing regimes fail to identify who is best suited for a given drug. All three of these prongs will shake out in time, but cause new problems as a result.
Where we’re at right now is less of a click-baity headline from The Economist, and more at the start of a new frontier in medicine that capitalizes on decades of research. We’ve maximized the benefits of “low-hanging” chemical-based drugs, and have moved into more complex, nuanced, or targeted drugs developed through modern compute rather than traditional drug trials alone. Things will change very quickly, and then stagnate again when we’ve picked clean the easy fruits from these new branches.
The second I read the print in Nature a bit ago I knew some version would show up here. I swear I’ve met deployed Marines less obsessed with staying awake through chemistry than some people here.
We have our NeuroLinkBrain Implant plugin to AI agent , so that you can vibe code 24/7 . To maximize shareholder value.
It also helps with non-work stuff that's just not fun to do, such as chores or filing your taxes. It even helps you stick with hobbies you actually enjoy but your brain gets bored of.
I had been looking into orexin agonists (along with other things like H3 autoreceptor antagonists) back when they were just a concept. It’s good to see them finally reaching commercialization. Although they’re not approved by our own (Canadian) regulatory body quite yet.
Now that they’re approved in the US, though, I’m looking very much forward to seeing how these drugs perform in off-label-ish treatment of the various other sleep disorders that I’m sure clinicians will now begin throwing them at.
> IMO the much more likely explanation is that the brain uses contrastive learning somewhere. [...] Instead of using calculus and outer products to calculate derivatives, you feed real data and false data forward through the network and each neuron tracks and trains on the difference.
- when learning on the real examples, just propagate forward
- when learning on the fake examples, first generate them by propagating white noise backward
Everyone involved in a stock market agrees it's quite useful to have a separation between days, although you could have a 23.5/7 stock market with only half hour day-ends. That's when things like index rebalancing, addition, removal, stock splits occur. You say whoever holds stock X at end of a certain day holds stock Y+Z at the start of the next day (due to a company splitting up) and there's no need to argue about which millisecond a trade occurred. (It's your own damn fault if you were trying to buy the stock in the milliseconds before closing, but some exchanges run a special closing auction with a different algorithm to prevent races). It's also the time you can deploy software, which you can't do during the day. Maybe half an hour is too short for all this stuff. Or maybe it should be a 12 hour window once a week instead.
Here’s the thing: what a lot of these drugs are doing are basically acting as equivalents to the store-bought neurotransmitters you’d find in things like SSRIs or -phetamines/stimulants. To people lacking in these substances, they’re game changers.
The problem right now is a mismatch between regulation, availability, and testing regimes. Regulations are meant to prevent dystopian shit like employers mandating (or encouraging) a drug regimen for employment through threat of punitive fines or prosecution, while the private insurance markets promote unaffordability domestically (as North America is where over half of pharma revenues come from) and testing regimes fail to identify who is best suited for a given drug. All three of these prongs will shake out in time, but cause new problems as a result.
Where we’re at right now is less of a click-baity headline from The Economist, and more at the start of a new frontier in medicine that capitalizes on decades of research. We’ve maximized the benefits of “low-hanging” chemical-based drugs, and have moved into more complex, nuanced, or targeted drugs developed through modern compute rather than traditional drug trials alone. Things will change very quickly, and then stagnate again when we’ve picked clean the easy fruits from these new branches.